mk2 Biotechnologies

The Finance Days at the analytica were a great opportunity for our CEO Konstantinos Antonopoulos to have a chat with a lot of fantastic people from the broader space and to develop creative solutions on the spot. If you're still around Munich and want to meet up, let us know! #proteins #peptides Christian Gnam IZB - Innovation and Start-up Center Biotechnology

Don't miss the opportunity to meet Priya Gurumoorthy, Ph.D. at the Meat Evolution Leaders Summit in Barcelona on Feb 7th/8th to check out our newest developments on growth factors and many more bioactive proteins.

We're excited to share that our former team member (and by that lifelong mk2 family member) Sarah Wali and her team BugSense Diagnostics were awarded yesterday with m4-Award by the BioM Biotech Cluster Development GmbH. The award provides a great framework and pre-seed funding to further develop and mature the BugSense urinary tract infections diagnosis tool that hopefully will enable a user-friendly diagnostic and personalized treatment for anyone. Congratulations!

In the ever-evolving field of immunology, antigen fragment vaccines 🔬 are sparking significant interest in both human and animal pharmaceutical realms 🧬. Antigen based vaccines are a weakened or an inactivated (killed) form of a virus or bacterium, or a small part of the virus or bacterium that cannot cause disease. They offer targeted immunogenicity stimulating a potent and specific immune response without the risks associated with whole pathogens. In addition, they are highly versatile and applicable against various infectious diseases. Identifying the ideal antigen fragment for vaccine development can be a lengthy and complex process. This is further supplemented with higher development and production costs compared to traditional vaccines💰. There is a need for cutting edge research and innovative platforms to overcome the hurdles associated with their production. At mk2 Biotechnologies, we have developed a disruptive protein purification platform technology targeting the production of antigen fragments at large scales in a cost-effective manner. Our purification technology enables their production at large volumes and at low costs, in a completely aqueous environment targeting the present existing production limitation. To know more, click here: www.mk2.bio/overview #Vaccines #Antigenfragments #AnimalPharma #HumanPharma